Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
GLP-1 Receptor Agonist Pregnancy: US label section 8.1: 'Limited data with BYETTA in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy. Based on animal reproduction studies, there may be risks to the fetus from exposure to BYETTA during pregnancy. BYETTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.' Animal data: 'In mice, exenatide administered during gestation and lactation caused increased neonatal deaths at systemic exposure 3-times the human exposure resulting from the maximum recommended human dose (MRHD) of 20 mcg/day for BYETTA.' This summary may be incomplete — check the full SPC.

Exenatide

Brand names: Byetta (twice daily), Bydureon (once weekly)

Exenatide is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycaemic control in type 2 diabetes.

Adult dose

Dose: Twice-daily (BYETTA) presentation only: 'Initiate BYETTA at 5 mcg administered subcutaneously twice daily' and, 'Based on clinical response, the dose of BYETTA can be increased to 10 mcg twice daily which is recommended after 1 month of therapy, in order to reduce the risk of gastrointestinal adverse reactions.'
Route: Subcutaneous injection in the thigh, abdomen, or upper arm - 'Rotate injections sites with each dose. Do not use the same site for each injection.'
Frequency: Twice daily, 'at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). Do not administer after a meal.'
Max: 20 mcg per day - the label refers to 'the maximum recommended human dose (MRHD) of 20 mcg/day for BYETTA' (section 8.1), which corresponds to the 10 mcg twice-daily maintenance dose above.
SCOPE: this bundle contains ONLY the twice-daily immediate-release product (BYETTA), which is the presentation this page's dose entry leads with; the once-weekly extended-release presentation carries a different regimen and is NOT sourced here - do not carry a weekly figure across without its own label. STRENGTHS (section 3): '5 mcg per dose in a single-patient-use prefilled pen containing 300 mcg/1.2 mL (250 mcg/mL), 60 doses' and '10 mcg per dose in a single-patient-use prefilled pen containing 600 mcg/2.4 mL (250 mcg/mL), 60 doses.' ADMINISTRATION (section 2.1): inspect visually and 'Only use BYETTA if the solution appears clear, colorless, and contains no particles'; 'When using BYETTA with insulin, administer as separate injections and never mix. It is acceptable to inject BYETTA and insulin in the same body region, but the injections should not be adjacent to each other'; 'If a dose is missed, resume the treatment regimen as prescribed with the next scheduled dose.' Never share a pen between patients, even if the needle is changed (section 5.2). CO-PRESCRIBING: 'When initiating BYETTA, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia' (section 7). NOT RECOMMENDED in patients with severe gastroparesis (section 5.5). PAEDIATRIC: paedDose is deliberately null - 'The safety and effectiveness of BYETTA have not been established in pediatric patients', and effectiveness was not demonstrated in a randomised, double-blind, placebo-controlled study in 120 patients aged 10 to 17 years with type 2 diabetes (section 8.4). Verify any under-18 use against a children's formulary. Some sections of the product information we used were incomplete — check the full SPC.

Dose adjustments

Renal

No renal-impairment dosing subsection was retrieved in this bundle, so no numeric renal adjustment is published. What the fetched sections do say: 'Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion' (section 5.4), and, for older patients, 'Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in the elderly based on renal function' (section 8.5). Confirm renal thresholds against the full label or the UK SPC before prescribing.

Hepatic

Not addressed in the retrieved sections of this label - no hepatic-impairment dosing statement was fetched.

Dose independently re-sourced from US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA - serious hypersensitivity reactions including anaphylaxis and angioedema have been reported (US label section 4)
  • A history of drug-induced immune-mediated thrombocytopenia from exenatide products - serious bleeding, which may be fatal, has been reported (section 4)

Side effects

  • Most common (5% or more and more frequent than placebo in clinical trials): nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia; 'Nausea usually decreases over time' (section 6)
  • Acute pancreatitis, observed with GLP-1 receptor agonists including BYETTA - discontinue if pancreatitis is suspected (section 5.1)
  • Hypoglycaemia, increased when used with an insulin secretagogue or insulin, including severe hypoglycaemia (section 5.3)
  • Acute kidney injury due to volume depletion (section 5.4)
  • Severe gastrointestinal adverse reactions - not recommended in patients with severe gastroparesis (section 5.5)
  • Immunogenicity - patients may develop antibodies to exenatide; consider alternative therapy if glycaemic control worsens or targets are not achieved (section 5.6)
  • Serious hypersensitivity reactions such as anaphylaxis and angioedema - discontinue and promptly seek medical advice (section 5.7)
  • Drug-induced immune-mediated thrombocytopenia with serious, potentially fatal bleeding (section 5.8)
  • Acute gallbladder disease (section 5.9) and pulmonary aspiration during general anaesthesia or deep sedation (section 5.10)

Monitoring

  • Renal function in patients reporting adverse reactions that could lead to volume depletion (section 5.4), and dose selection in the elderly guided by renal function (section 8.5)
  • Blood glucose for hypoglycaemia when combined with an insulin secretagogue or insulin, reducing the dose of that agent when starting BYETTA (sections 5.3, 7)
  • Prothrombin time / INR in patients taking warfarin - 'monitored more frequently after initiation or alteration of BYETTA therapy' until stable, following post-marketing reports of increased INR sometimes associated with bleeding (section 7)
  • Watch for pancreatitis and discontinue if it is suspected (section 5.1)
  • Glycaemic response over time - if there is worsening glycaemic control or failure to achieve target, consider antibody formation and alternative antidiabetic therapy (section 5.6)
  • Absorption of other oral medicines may be affected - BYETTA 'May impact absorption of orally administered medications' (section 7)

Clinical monograph

How it works

It activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying and increase satiety.

Prescribing in practice

  • It has been associated with acute pancreatitis, so it should be stopped and not restarted if pancreatitis is suspected.
  • Gastrointestinal effects, especially nausea, are common, and the prolonged-release formulation must not be confused with the immediate-release product.
  • Hypoglycaemia risk is increased when combined with a sulfonylurea or insulin, which may need dose reduction, and it is not recommended in severe renal impairment.

Monitoring

Monitor HbA1c and renal function, and review gastrointestinal tolerability after initiation and dose changes.

Counselling the patient

  • Stop the medicine and seek urgent advice for severe, persistent abdominal pain.
  • Nausea is common early on and usually settles; take as directed for your specific formulation.
  • Report symptoms of low blood sugar, especially if you also take a sulfonylurea or insulin.

Evidence & guidelines

NICE recommends GLP-1 receptor agonists such as exenatide for type 2 diabetes within defined treatment criteria.

Reference: NICE NG28 (Type 2 DM); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways